Group | No change | Regression | Progression | ||||
n | n | OR (95% CI)* | p Value | n | OR (95% CI)* | p Value | |
Intention-to-treat analysis | |||||||
Placebo | 78 | 99 | 1.00 | 57 | 1.00 | ||
Anti-Hp+celecoxib | 59 | 114 | 1.50 (0.97 to 2.32) | 0.067 | 47 | 1.06 (0.63 to 1.78) | 0.833 |
Anti-Hp+placebo | 55 | 126 | 1.80 (1.16 to 22.78) | 0.009 | 52 | 1.24 (0.74 to 2.09) | 0.411 |
Celecoxib+placebo | 61 | 120 | 1.55 (1.01 to 22.38) | 0.046 | 51 | 1.13 (0.68 to 1.89) | 0.637 |
Per-protocol analysis | |||||||
Placebo† | 67 | 82 | 1.00 | 50 | 1.00 | ||
Anti-Hp+celecoxib‡ | 47 | 84 | 1.48 (0.91 to 2.40) | 0.117 | 30 | 0.83 (0.45 to 1.51) | 0.537 |
Anti-Hp+placebo‡ | 36 | 96 | 2.19 (1.32 to 3.64) | 0.002 | 30 | 1.08 (0.58 to 2.02) | 0.805 |
Celecoxib+placebo† | 49 | 102 | 1.72 (1.07 to 2.76) | 0.026 | 42 | 1.14 (0.65 to 2.00) | 0.658 |
↵* ORs and 95% CIs were calculated by logistic regression and adjusted for age, sex, smoking and drinking status.
↵† The participants who remained H pylori positive.
↵‡ The participants in whom H pylori was eradicated (negative by carbon-13 urea breath test after 45 days).
Anti-Hp, anti-H pylori treatment.